Table 2.

Baseline systemic autoimmune rheumatic disease characteristics at time of initial tixagevimab/cilgavimab receipt

Characteristic	SARD patients who received tixagevimab/cilgavimab (n=444)
SARD diagnosis
Rheumatoid arthritis	194 (43.7%)
Systemic lupus erythematosus	66 (14.9%)
ANCA-associated vasculitis	52 (11.7%)
Psoriatic arthritis	17 (3.8%)
Systemic sclerosis	14 (3.2%)
Sjogren’s disease	13 (2.9%)
Polymyalgia rheumatica and/or giant cell arteritis	20 (4.5%)
Idiopathic inflammatory myositis	12 (2.7%)
Axial and peripheral spondyloarthritis	6 (1.4%)
Mixed connective tissue disease	6 (1.4%)
Multiple primary rheumatic diseases	21 (4.7%)
Other diagnosesa	22 (5.0%)
Immunomodulatory medications
DMARDs	433 (97.5%)
Biologic DMARDs	298 (67.1%)
CD20 inhibitor	216 (48.7%)
TNF inhibitor	37 (8.3%)
IL-6 receptor inhibitor	18 (4.1%)
CTLA-4 immunoglobulin	17 (3.8%)
B-cell activating factor inhibitor	8 (1.8%)
IL-17, IL-12/23, or IL-23 inhibitor	5 (1.1%)
Targeted synthetic DMARD
JAK inhibitor	11 (2.5%)
Conventional synthetic DMARDs	289 (65.1%)
Methotrexate	98 (22.1%)
Mycophenolate mofetil / mycophenolic acid	91 (20.5%)
Antimalarials	85 (19.1%)
Calcineurin inhibitorb	63 (14.2%)
Azathioprine	29 (6.5%)
Leflunomide	22 (5.0%)
Cyclophosphamide	14 (3.2%)
Sulfasalazine	12 (2.7%)
Oral glucocorticoid	52 (11.7%)

SARD, systemic autoimmune rheumatic disease; ANCA, antineutrophil cytoplasmic antibody; DMARD, disease-modifying antirheumatic drug; TNF, tumor necrosis factor; IL, interleukin; CTLA-4, cytotoxic T-lymphocyte associated protein 4; JAK, Janus kinase

^aIncludes IgG4 related disease, sarcoidosis, relapsing polychondritis, adult-onset Still’s disease, other inflammatory arthritis, juvenile idiopathic arthritis, primary antiphospholipid antibody syndrome, Behçet disease, and Takayasu arteritis

^bIncludes tacrolimus, cyclosporine, and voclosporin